The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

AFL great, turned Cerutty Macro Fund portfolio manager, Chris Judd is with HP Rx founder and managing partner Hashan De Silva for today’s Talk Ya Book.

They discuss CurveBeam AI (ASX:CVB), a company in which Mr De Silva is a director. Mr De Silva holds 565,493 ordinary shares, millions of options and 320,928 indirect shares.

The company’s developed a CT scanning device, called HiRise, that works when a patient is weight-bearing, providing imaging while patients are standing. The images can be done within an orthopaedic centre, and release lower radiation levels.

CurveBeam has a market cap of $36 million and was trading at 16 cents (May 28).

KP Rx invests in a diverse range of biotech, medical device, diagnostic, and health tech companies located predominantly in Australia and New Zealand. It is backed by Karst Peak Capital.

Talk Ya Book was created by Chris Judd in 2019 as a show where fund managers could share their highest conviction investment idea but more importantly showcase their investment framework to the public.

Disclaimer: Juddcorp Pty Ltd ACN 635 629 631 is a corporate authorised representative (CAR) (CAR Number 1300536) of Boutique Capital Pty Ltd ACN 621 697 621 AFSL 508011.

The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.

More From The Market Online
Dale Gillham's photo, and wording 'Words from Wealth Within's Chief Analyst Dale Gillham.

Virgin returns to the ASX: Buy the hype or wait for a dip?

The return of Virgin Australia to the ASX is one of the most anticipated IPOs of 2025. With Bain Capital reducing its stake...

Proteomics claims it can diagnose throat cancer with blood test

Proteomics International (ASX:PIQ) has popped +6% after reporting the "high accuracy" of its blood test for…
A man lies in a hospital bed receiving an IV drip.

‘Critical step’: Go for Recce’s Phase III trials after banking $15.8M in capital raise

Recce Pharmaceuticals (ASX:RCE) has successfully filled its coffers ahead of its Phase III clinical trials in Indonesia and Australia,
Model of a knee

Paradigm activates first Aus site for osteoarthritis drug trials

Paradigm Biopharmaceuticals Ltd has opened its first Australian site as part of a trial to assess…